Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology
Phase 2 data evaluating ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) in patients with Type 2 diabetes demonstrated lower blood glucose levels following ZILRETTA injection compared to TAcs injection Approximately 30% of patients with Type 2 diabetes also have
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 10,500 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference
BURLINGTON, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will present at the 13 th Annual Wells Fargo Securities Healthcare Conference taking place at the Westin Copley Place in Boston, Massachusetts .
View HTML
Toggle Summary Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium
Military Health System provides healthcare to more than nine million people; the research symposium highlights scientific advancements that impact military medicine  Osteoarthritis is a leading cause of disability discharge from the military Post-hoc analysis showed those treated with ZILRETTA ®
View HTML
Toggle Summary Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights
Company reported net ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) sales of $3.8 million in Q2 representing 73% growth over Q1 Strong progress on the ZILRETTA commercial launch: 60% of target accounts have either purchased, or received samples of, ZILRETTA; more than
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 14,800 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018
BURLINGTON, Mass. , July 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, August 7, 2018 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , July 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to nine new employees for an aggregate of 30,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row
BURLINGTON, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named as one of the Boston Business Journal’s “Best Places to Work” for the second year in a row. Flexion was ranked among the top 15 companies in the medium business
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , June 01, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML